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Abstract
Background: Multidrug resistance (MDR) is one of the major problems in the treatment of cancer. Overcoming it is
therefore expected to improve clinical outcomes for cancer patients. MDR is usually characterized by overexpression
of ABC (ATP-binding cassette) protein transporters such as P-gp, MRP1, and ABCG2. Though the importance of ABC
transporters for cancer cells is recognized, few studies have looked at its implications for the endothelial cells that
are essential to tumor angiogenesis. This study investigated the expression and functions of these ABC transporters
in endothelial cells in vitro and their potential contribution to cancer growth in mice.
Methods: Human micro vessel endothelial cells (HMEC-1) and human umbilical vein endothelial cells (HUVEC) were
exposed to increasing doses of Doxorubicin (Dox) to induce ABC gene expression. Cell viability was then quantified
by 3H-thymidine and MTS assay. Flow cytometry, qPCR, and western blot were used to detect mRNA and the
protein expression of P-gp, MRP1, and ABCG2. The intracellular accumulation of Rhodamine 123 (Rho) was used to
evaluate drug efflux function and the inhibitors for P-gp, ABCG2, and MRP1 were used to verify their respective
roles in vitro. In an attempt to evaluate drug resistance in endothelial cells in vivo, athymic mice were treated with
Dox for 15 days before a MDA-MB-435 tumor graft to observe subsequent changes in the inhibition curves of
tumor growth in response to Dox treatment. Furthermore, endothelial cells from multiple sites in these mice were
also isolated to estimate their P-gp expression by flow cytometry.
Results: Drug resistance in HMEC-1 and HUVEC was successfully induced by the addition of Dox to the culture
media. Two stabilized subcell lines of HMEC1 (HMECd1 and HMECd2) showed 15- and 24-fold increases in
resistance. Tests also showed that these induced endothelial cells were cross-resistant to the structurally unrelated
drugs Daunorubicin, Vinblastine, and Etoposide. P-gp protein levels increased four and six fold in HMECd1 and
HMECd2 as revealed by western blot. The qPCR demonstrated 3.4- and 7.2-fold increases in P-gp, and a slight
increase in ABCG2, gene expression. The Rho accumulation within these cells was inversely correlated with the
expression levels of P-gp. The inhibitors of P-gp, but not of ABCG2 or MRP1, were able to block the induced
endothelial cell resistance to Dox. Furthermore, we also showed that injecting Dox into healthy mice induced an
increase in P-gp expression in endothelial cells. Using these pretreated mice in a tumor growth experiment, we
observed a dramatic diminution in the therapeutic efficiency of Dox treatment, suggesting implications for drug
resistance in mice endothelial cells supporting tumor growth.
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Conclusions: ABC transporter expression can be induced in endothelial cells in vitro. This study also indicates that
P-gp plays an important role in the acquisition of resistance to Dox in endothelial cells and that this reduces the
efficiency of chemotherapy.
Keywords: Drug resistance, Endothelial cells, ATP-dependent transporter, Anti-cancer therapy
Introduction
Recent antitumor drug research has seen the development
of a large variety of antiangiogenesis therapies. Because
cancer cells in tumors require new blood vessels to grow
and spread, they stimulate capillary sprouting from
existing vessels and new vessel formation from endothelial
precursor cells [1-4]. Recent clinical data shows benefit
from the combined administration of antiangiogenic and
cytotoxic (chemo- and radiation) therapies, because such
combinations target two separate compartments of tumor
cancer and endothelial cells. However, recent studies show
that antiangiogenic agents also have a direct effect on
tumor cells [5,6]. It is also the case that the cytotoxic
agents used in chemo- and radiotherapy also affect endo-
thelial cells and inhibit angiogenesis vice versa [7-9].
Drug resistance is an obstacle that impairs the success
of cancer therapies. In some cases relapse occurs in ini-
tially responsive patients after repeated cycles of chemo-
therapy due to the acquisition of tumor resistance [10].
Multiple mechanisms contribute to drug resistance, such
as increased drug efflux, altered drug metabolism, sec-
ondary mutations in drug targets, and the activation of
downstream or parallel signal transduction pathways
[11,12]. The critical mechanism of cell drug resistance
involves the ABC (ATP-binding cassette) protein trans-
porters which pump drug molecules out of cells, leading
to reduced effective concentration within them [13].
Well-known ABC transporters include the multidrug re-
sistance (MDR) protein or P-glycoprotein (MDR1, P-gp,
ABCB1); the multidrug resistance-associated proteins
(MRP1, ABCC1); and the breast cancer resistance pro-
teins (BCRP, ABCG2) [14,15].
P-gp is the first protein to have been shown to be in-
volved in the MDR phenomenon and to be overexpressed
primarily in cancer cells [16,17]. It is a protein of 170 kDa
containing 1280 amino acids (aa) organized into 12 putative
transmembrane domains shared out among two adenosine
triphosphate (ATP)-binding cassettes [18,19]. Its role is well
established in hepatic drug excretion and limitation of the
gastrointestinal absorption of substrate drugs, and as a key
component of the blood–brain, blood-testicular, and blood-
placental barriers [13,20-24]. It is also expressed in circulat-
ing cells such as CD34+ hematopoietic progenitor, CD8+T
cells or natural killer cells [25]. Upregulation of P-gp has
previously been shown to increase cancer cells’ ability to
efflux a wide variety of structurally unrelated chemothera-
peutics such as Vinca alkaloids (Vincristine, Vinblastine),
Anthracyclins (Doxorubicin [Dox], Daunorubicin), and
Epipodophyllotoxins (Etoposide) [26-28]. Like P-gp, MRP1
and ABCG2 also have wide broad-substrate specificity [29].
All three molecules are reported as being expressed in
endothelial cells [30-35].
Several published observations report high level expres-
sion of P-gp in tumor endothelial cells [36,37]. In this
study, we characterize the induction of a major ABC pro-
tein in Human micro vessel endothelial cells (HMEC-1)
and human umbilical vein endothelial cells (HUVEC) in
response to long-term Doxorubicin treatment. The func-
tional tests are then used to evaluate the protein function.
Finally, the athymic mice are treated with Dox to observe
the possible occurrence of induced drug resistance in
mouse vessels. Our results suggest that P-gp overexpres-
sion in endothelial cells could be an early event in the de-
velopment of chemoresistance and may contribute to the
resistant phenotype of tumors in vivo. This observation
may be helpful when designing novel therapeutic strat-
egies to improve cancer outcomes.
Materials and methods
Material
Mouse monoclonal antibodies against human P-gp:
C219 were obtained from Calbiochem, La Jolla, CA; 4E3
from Dako, Glostrup, Denmark; and 265/F4 from
Abcam, Paris, France. Antibody MRK16 blocking P-gp
function was obtained from Kamiya Biomedical Com-
pany (Seattle, WA). The anti-ABCG2 antibody BXP-21
came from Abcam and the anti-MRP1 antibody QCRL-1
from Santa Cruz Biotechnology Inc., CA. The antibodies
against vWF, flt-1, CD31, or CD105 as well as the FITC
or HRP-conjugated F (ab’)2 fragment of goat anti-mouse
IgG were all provided by Dako. Doxorubicin chlorhy-
drate was purchased from Amersham Pharmacia Biotech
(Uppsala, Sweden). Rhodamine 123 and Verapamil were
obtained from Calbiochem and Daunorubicin, Etopo-
side, Vinblastine, Cyclosporine A, Fumitremorgin C, and
Diethylstibesterol Terfenadine were provided by Sigma
Chemical Co. (Saint Louis, MO).
Cell culture
Parental and resistant HMEC-1 (Dr TL Lawley, Depart-
ment of Dermatology, Atlanta) lines were cultured in
MCDB-131 medium supplemented with 10% fetal calf
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serum (FCS), 2 mM L-glutamine, 10 ng/ml EGF, 1 μg/ml
hydrocortisone, 100 units/ml penicillin, and 100 μg/ml
streptomycin as described elsewhere [38]. Dox-resistant
HMEC cells were obtained by continuously exposing
cells to escalating concentrations of Dox from 0.001 μg/ml
to 0.24 μg/ml over a 12-week period. Two subcell lines of
HMEC-1 cells were collected: one was maintained in a
culture with 0.08 μg/ml Dox (HMECd1 cells), and another
with 0.24 μg/ml Dox (HMECd2 cells). No mutagenic
agents were used in the establishment of these Dox-
resistant HMEC cells. In the experiments looking at the
reversibility of Dox resistance, both HMECd1 and
HMECd2 cell lines were cultured in complete medium
without Dox for four weeks. HUVEC were isolated as
reported elsewhere [39] and seeded on a 1% gelatin-
coated plastic flask in MEM-199 medium supplemented
with 20% FCS, 15 mM sodium bicarbonate, 15 mM hepes,
2 mM L-glutamine, 10 ng/ml EGF, 1 μg/ml hydrocorti-
sone, 100 units/ml penicillin, and 100 μg/ml streptomycin.
Human breast adenocarcinoma cells MDA-MB-435 were
cultured in DMEM medium containing 10% FCS, 2 mM
sodium pyruvate, 1 mM L-glutamine, 100 units/ml peni-
cillin, and 100 μg/ml streptomycin. All types of cells were
digested with trypsin-EDTA once or twice a week and cul-
tured in a 37°C incubator with a 100% humidified atmos-
phere of 5% CO2.
3H-thymidine Cell proliferation assay
Parental and resistant HMEC sublines were seeded at a
density of 4 x 104 cells per well in 48-well culture plates
and exposed to a range of drug concentrations for
72 hours at 37°C in an atmosphere of 5% CO2. After
70 hours incubation, 1 μCi 3H-thymidine (Amersham
Pharmacia biotech) was added per well for 2 hours.
Wells were then washed twice in PBS and successively
incubated with 5% trichloroacetic acid for 20 minutes at
4°C and then 0.5 N NaOH for 90 minutes at 37°C.
Radioactivity incorporated into adherent cells was recorded
on a β counter (Beckman). The 50% cytotoxic concentra-
tion (IC50) values were defined as the drug concentration
producing 50% inhibition of cell growth and the resistance
index (RI) corresponded to the ratio of IC50 values be-
tween the resistant and parental cell lines.
MTS cell proliferation assay
Cell viability was determined using the MTS cell prolif-
eration assay (Promega). Cells grew to a confluence of
90% in 75 cm2 cell culture flasks and were passed into
96-well plates (7500 cells/well). Each well contained
100 μl of culture medium supplemented with various
concentrations of drugs or with a concentration of
DMSO as control. After incubation for either 24, 48, or
72 hours, 20 μl of the MTS reagent was added to each
well, and the plate placed in the 5% CO2 incubator at
37°C for an additional 2 hours. The optical density (OD)
was then read at 492 nm using a microplate reader
(Labsystems Multiskan MS). The IC50 values were de-
fined as the concentration of drug producing 50% inhib-
ition of cell growth and the RI corresponded to the ratio
of IC50 values between the resistant and parental cell
lines. Experiments were performed in triplicate and re-
peated at least three times.
Blocking effect assay
P-gp inhibitors Cyclosporine A at 2.5 μM or Verapamil
at 1 μM and ABCG2 inhibitors Fumitremorgin C at
5 μM or Diethylstibesterol at 0.5 μM were used in these
experiments. After incubation for 48 or 72 hours, cell
viability was assessed by the MTS assay. The reversal
fold (RF) values, as a measure of the potency of reversal,
were obtained from fitting the data to RF = IC50 of cyto-
toxic drug alone/IC50 of cytotoxic drug in the presence
of a modulator [40].
Rhodamine-123 (Rho) accumulation and efflux assay
HMEC-1, HMECd1, and HMECd2 cells (106/ml in PBS-
BSA) were incubated with 1–2 μg/ml Rho in the dark at
37°C in 5% CO2 for one hour. Then, the cells were
washed twice with ice-cold PBS and analyzed immedi-
ately using flow cytometry at different time points. To
test Rho efflux specificity, cells were incubated with
30 μM Verapamil or 10 μg/ml MRK16. Results were
expressed in an arbitrary unit of the mean fluorescence
intensity (MFI). The drug efflux was expressed relative
to the amount of drug accumulated.
Evaluation of mRNA expression via qPCR
HMEC-1, HMECd1, and HMECd2 cells were treated
with 2.5 μM Cyclosporine A, 1 μM Verapamil, 5 μM
Fumitremorgin C, or 0.5 μM Diethylstibesterol for
24 hours. After incubation, the treated and non-treated
cells were harvested and total RNA prepared using the
SV total RNA isolation system kit (Promega, USA). The
purity of total RNA was checked by a ratio of A260/
A280 (>1.9). Total RNA (50 ng) was used to synthesize
the first-strand cDNA in a 20 μl reaction solution using
the GoScript Reverse Transcription System kit (Promega,
USA). Then, 2 μl of cDNA was used for qPCR in tripli-
cates using a taqman® gene expression assay, the primers
for P-gp (Hs01067802_m1), ABCG2 (Hs01053790_m1),
and the primers for TBP as controls (TATA box binding
protein, Hs99999910_m1, Applied Biosystem). The qPCR
was performed by 10 minutes of initial denaturation
followed by 44 cycles of 15 s at 95°C and 60 s at 60°C in a
BioRad CFX96® Real-time System. Delta Ct method was
used for analyzing the qPCR results and TBP was used as
an internal control for mRNA-level normalization.
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Evaluation of protein expression using western blot
analysis
Western blot was performed on whole cell lysates by
incubating the cells in the lysis buffer (10 mM Tris
pH 6.8, 1 mM EDTA, 10% NP40, 1 mM PMSF, 0.1%
SDS) on ice for 30 minutes. Cell debris was removed by
centrifugation at 16000 g for 10 minutes. Protein con-
centration was determined by BCA™ protein assay
(Thermo Scientific, USA). A 50 μg protein of each sam-
ple was loaded on 8% SDS-PAGE, and the protein trans-
ferred to a PVDF membrane by the iBlot™ dry blotting
system (Invitrogen, USA). The membranes were blocked
by 5% nonfat dry milk for one hour and incubated with
either anti-P-gp (Abcam ab-3364) or anti-ABCG2 anti-
bodies (Abcam ab-3380) at 4°C overnight. They were
then washed with TBS-tween buffer for one hour and in-
cubated with appropriate HRP-conjugated secondary
antibodies (Invitrogen Corp) diluted in blocking buffer
for one hour at room temperature. After washing, west-
ern blotting luminol reagent (Santa Cruz Biotechnology,
USA) was added to the membranes and the chemilumin-
escence recorded using a Fuji LAS-3000 system. The
membranes were then treated with antibody stripping
buffer (Gene Bio-application Ltd. Israel), and incubated
with anti-actin antibody (1:4000 dilution, Sigma, USA)
as control.
In vivo assays
Mice were maintained under specific pathogen-free con-
ditions in the animal facility of the Institut Universitaire
d’Hématologie, Saint Louis Hospital in Paris. All experi-
mental procedures were performed in accordance with
the recommendations of the European Community (86/
609/EEC) and the French National Committee (87/848)
for the care and use of laboratory animals. Female
athymic nude mice Nu/Nu Swiss (9 weeks of age) (Iffa-
credo, France), weighing 18–22 g, were housed under
controlled environmental conditions (approximately 25°C)
with commercial food and water freely available. Primary
results showed that the maximal tolerated dose of Dox by
athymic mice for a 6 week period was 6 mg/kg/week. Dox
was prepared in 0.9% sodium chloride and ip injections
given twice weekly. The experimental procedure consisted
of a pretreatment of the mice for 15 days with sodium
chloride as a control or 6 mg/kg/week Dox. MDA-MB-
435 cells (4×106 cells/200 μl PBS) were then injected
subcutaneously into their dorsal midline. Tumor growth
was determined 25 days after cell injection and sizes
monitored by measuring two diameters with a dial-
caliper. Tumor volume was calculated as TV = length ×
(width)2 × π/6.
At the end of the experiments, the mice were sacrificed
and the percentage of endothelial cells expressing P-gp on
the liver, kidneys, heart, and tumor measured by flow cy-
tometry. Tissues were cut into approximately 1×1-mm2
squares and rinsed in physiologic serum. The pieces were
incubated with 2 mg/ml collagenase at 37°C for 20 minutes
with frequent agitation. The cell suspension obtained fol-
lowing extensive trituration with a 5 ml pipette was fil-
tered on a 70 μm nylon cell strainer followed by a second
40 μm filtration. The second filtrates were centrifuged at
1200 rpm for 5 minutes and the pellets washed twice in
1 ml PBS containing 0.5% BSA. Endothelial cells were iso-
lated by immunoabsorption on magnetic beads coated
with anti-mouse CD31 and CD105 IgG according to the
recommended protocol (Myltenyi Biotec, France). The
isolated cells were characterized by flow cytometry using
anti-mouse vWF IgG or C219 antibody. Labeling was re-
vealed by second incubation with fluorescein-conjugated
goat anti-mouse IgG.
Immunohistochemical staining
Immunohistochemical studies were carried out on 5 μm
paraffin sections before and after treatment. Primary
antibody against P-gp C219 antibody was used at 1:50
dilution. All the immunostainings were performed in an
automated immunostainer (Ventana Medical System,
France). The intensity and percentage of the cytoplasmic
staining on tumor sections were noted.
Statistical analyses
Data were analyzed using one-way ANOVA and
Mann–Whitney U tests as appropriate. The data of
qPCR, invasion assay, and in vivo data are presented as
mean ± SEM. The rest of the data is presented as mean ±
SD. A probability value of ≤ 0.05 was regarded as statisti-
cally significant.
Results
Multidrug resistance of endothelial cells
Our experiments showed that HMEC-1 cells are initially
sensitive to Dox treatment. In our attempt to study the
induction of drug resistance in endothelial cells, we
added progressively increasing doses of Dox into the cul-
ture media of the HMEC-1 cells during a period of ap-
proximately 12 weeks. When the cells had gradually
adapted to the presence of higher concentrations of
Dox, two conditions were then chosen to stabilize the
Dox-resistant endothelial cell: one population was main-
tained in a culture with 0.08 μg/ml Dox (HMECd1), and
another with 0.24 μg/ml Dox (HMECd2). As shown in
Table 1, MTS assay indicated a 15- and 24-fold increase
in drug-resistance in the stabilized subcell lines HM
ECd1 and HMECd2, as compared to their parental cells.
3H-thymidine incorporation assay indicated a 36- and
178-fold increase in the RI of HMECd1 and HMECd2
cells in comparison to the parental HMEC cell line
(Table 2). Their cellular characteristics were close to
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those of the parental cells as shown by comparable
morphologies and equivalent expression levels of von
Willebrand factor, CD31, CD105, flt1, and E-cadherin
(data not shown). When we assessed the stability of the
Dox-resistant phenotype by culturing HMECd2 in the
absence of drugs, we found that after 2 weeks in a drug-
free medium, there was no significant change in the drug
resistance phenotype or resistance index. However, when
grown without selection pressure for 4 weeks, the RI to
Dox decreased from 178.5 to 1.25 (p < 0.001). Therefore,
endothelial cells were able to induce or reverse the ex-
pression of P-gp.
The resistance of these cells to other drugs was then
tested. The use of three MDR-related drugs, Daunorubi-
cin, Vinblastine, or Etoposide, showed that both of the
Dox-resistant endothelial cell lines were also resistant to
higher concentrations of these drugs compared to paren-
tal cells (Table 2). In contrast, no significant differences
between parental and resistant sublines were found with
Mytomycin C treatment (Table 2).
P-gp is predominantly expressed in the resistance of
endothelial cells
Flow cytometric studies demonstrated a high level of
P-gp expression on the cell surface of Dox-treated cells,
whereas it was almost absent on parental cells (Figure 1a
and b). P-gp surface expression was dependent on the
Dox concentration used for cell establishment; it reached
9.2 ± 2.9 MFI for HMECd1 cells (p < 0.05) and 45.1 ± 8.4
MFI for HMECd2 cells (p < 0.005) compared with 2.8 ±
0.8 MFI for parental cells. This P-gp expression repre-
sented a 3.2- and 16-fold increase in comparison with par-
ental cells. Interestingly, when treated with 0.16 μg/ml
Dox for 15 days, a primary culture of endothelial cells
isolated from the human umbilical vein also expressed a
P-gp protein on their surface (Figure 1b). In contrast, we
did not find any expression of MRP1 in both Dox-
resistant HMEC and HUVEC (data not shown)
Western blot analysis of the levels of P-gp showed that
its expression in drug-resistant HMECd1 and HMECd2
cells increased about 4- and 6- fold, respectively (Figure 1c).
Furthermore, we also determined the changes of P-gp
mRNA levels using qPCR. The results showed an increase
in P-gp mRNA by approximately 3.4 and 7.2 folds in
HMECd1 and HMECd2 cells, respectively regardless of
the presence of the P-gp or ABCG2 inhibitors (Figure 1e).
Levels of ABCG2 expression on drug-resistant HMECd1
and HMECd2 cells were also evaluated using qPCR and
western blot. Our results showed a 1.41- and 1.68-fold in-
crease in ABCG2 mRNA in HMECd1 and HMECd2 cells,
regardless of the presence of the ABCG2 or P-gp inhibi-
tors (Figure 1f). The ABCG2 protein also increased about
1.5 and 2 fold, respectively (Figure 1d). Thus, our results
indicate that Dox induced predominantly P-gp expression.
Dox-induced P-gp mediates endothelial cells’ resistance
to Dox
Transporter functionality was tested by evaluating the
ability of these cells to efflux a fluorescent Rho probe.
Kinetic analyses by flow cytometry showed that parental
cells incorporated the fluorescent probe in a time-
dependent manner, reaching a plateau of 41.2 ± 7.9 MFI
Table 1 Modulation of drug resistance to Dox by Verapamil and Cyclosporine A in HMECd1 and HMECd2
HMEC-1 HMECd1 HMECd2
Agents IC50 (μM) IC50 (μM) RI RF IC50 (μM) RI RF
Dox 0.052 ± 0.001 0.785 ± 0.049 15.09* 1.00 1.257 ± 0.055 24.17* 1.00
+ Vrp 1 μM 0.051 ± 0.002 0.386 ± 0.075 7.56* 1.99* 0.225 ± 0.062 4.41* 5.59*
+ CysA 2.5μM 0.049 ± 0.004 0.251 ± 0.041 5.12* 3.13* 0.159 ± 0.057 3.24* 7.91*
The cells were treated as described and tested by MTS assay. The resistance index (RI) was determined as the IC50 of Dox-treated HMECd1 or HMECd2 cells
divided by the IC50 of Dox-treated HMEC-1 cells. The resistance fold (RF) was calculated as the IC50 of Dox-treated HMECd1 or HMECd2 cells over the IC50 of the
same cell line as treated by Dox plus P-gp inhibitors. *p <0.05 for statistical significance.
Table 2 Cross-resistance of HMECd1 and HMECd2
IC50 μg/ml (RI)
HMEC-1 HMECd1 HMECd2
Doxorubicin 0.0028 ± 0.0003 (1) 0.1 ± 0.027 (35.7)* 0.5 ± 0.01 (178.5)*
Daunorubicin 0.018 ± 0.009 (1) 0.92 ± 0.01 (51.1)* 1.7 ± 0.78 (94.4)*
Vinblastine 0.023 ± 0.007 (1) 0.16 ± 0.03 (69.5)* 0.2 ± 0.03 (86.9)*
Etoposide 0.0031 ± 0.0006 (1) 0.062 ± 0.0062 (20)* 0.6 ± 0.094 (203.5)*
Mytomycin C 0.16 ± 0.0074 (1) 0.15 ± 0.071 (0.9) 0.18 ± 0.0003 (1.1)
The cells were cultured for 72 hours at 37°C in the presence of increasing concentrations of Dox, Etoposide, Daunorubicin, Mytomycin C, or Vinblastine, then
incubated with 1 μCi 3H-thymidine/well for 1 hour at 37°C. The radioactivity incorporated into the cell was then measured. IC50 were determined over three
separate experiments. Results are expressed as the mean ± SEM. *p <0.05 for statistical significance.
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at 80 minutes (result not shown). In contrast, both Dox-
resistant cell lines demonstrated a significant decrease in
Rho accumulation (indicative of an enhanced efflux),
reaching 13.1 ± 3.9 MFI for HMECd1 and 6.9 ± 1.3 MFI
for HMECd2 at 80 minutes (p < 0.025). This indicated a
68% and 83% reduction in intracellular Rho accumula-
tion (Figure 2a). Similar experiments with Dox-treated
and untreated HUVECs showed that only the former
could significantly and specifically efflux Rho (p < 0.05)
(Figure 2b). When incubating both Dox-resistant HMEC
cells in the presence of 5 μM Rho for one hour at +4°C,
to block the energy-dependent function of P-gp, the Rho
uptake reached ≈ 34.5 MFI, a comparable value to that
of 38.4 ± 3.3 MFI obtained for parental cells. By analyz-
ing data obtained during the establishment of Dox resist-
ance, we demonstrated a linear correlation between P-gp
Figure 1 Induced P-gp-mediated drug resistance of endothelial cells. P-gp cell surface expression was analyzed with flow cytometry in
HMEC (Panel a) or HUVEC cells (Panel b). Endothelial cells expressed P-gp after the induction by Dox treatment. Parental (thick black line),
HMECd1 and HUVECd3 (thin black line), and HMECd2 (−−) cells were incubated with 10 μg/ml 4E3. Incubation with control IgG2a gave similar
histograms for the three cell lines (filled grey histogram). Histograms are representative of four separate experiments. Panel c: The western blot of
P-gp levels in HMECd1, HMECd2 and their parental cells. The data for the ratio were obtained with three repeated blots. *: p < 0.05 in
comparison with the controls. Panel d: The western blot of ABCG2 levels in these cells. The data for the ratio were obtained with three repeated
blots. *: p < 0.05 versus the controls. Panel e: qPCR (primer Hs01067802_m1) results of P-gp mRNA levels in treated or nontreated HMEC-1,
HMECd1, and HMECd2. Cyclosporine A (C), Verapamil (V), Fumitremorgin C (F), and Diethylstibesterol (D) were used to treat the cells. The results
were obtained from three independent experiments. *: p < 0.05 versus the nontreated cells. Panel f: qPCR (Hs01053790_m1) results of ABCG2
mRNA levels in treated or nontreated HMEC-1, HMECd1, and HMECd2. Cyclosporine A (C), Verapamil (V), Fumitremorgin C (F), and
Diethylstibesterol (D) were used to treat the cells. The results were obtained from three independent experiments. *: p < 0.05 versus the
nontreated cells. Panel g: Correlation between P-gp surface expression and its efflux function. During the establishment of resistant HMEC cell
lines, the P-gp surface expression and the Rho efflux were regularly analyzed by flow cytometry, as shown in Figure 2a-d (R2 = 0.9301).
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transporter expression and its Rho efflux function as
confirmed by a correlation factor R2 of 0.9301 (Figure 1g),
indicating P-gp plays a major role in drug efflux in these
cells.
Blocking P-gp attenuates the resistance of endothelial
cells to Dox
We tested the effects of two functional inhibitors of P-gp,
Verapamil and the MoAb MRK16, on Rho accumulation
(Figure 2a-d). The presence of Verapamil did not signifi-
cantly modify the Rho accumulation in parental HMEC
cells (Figure 2c, d). In contrast, it effectively blocked efflux
of the fluorescent dye in both Dox-resistant cell lines, rais-
ing them significantly to an intracellular Rho level com-
parable to that of parental HMECs (Figure 2c, d). The
very low Rho accumulation (2 μM) in HMECd1 and
HMECd2 cells increased to 96.1 ± 4.9 MFI (p < 0.01) and
73.45 ± 2.5MFI (p < 0.025) respectively when 30 μM Ver-
apamil was added. Varying the concentration of Verapamil
from 1 to 100 μM resulted in a progressive increase of
intracellular Rho accumulation, indicating its specific ef-
fect. This reached a plateau at 30 μM (data not shown).
The presence of the specific P-gp inhibitory MoAb,
MRK16, reproduced the effect of Verapamil and restored
a level of Rho accumulation in both HMECd1 and
HMECd2 similar to that of parental cells (Figure 2d). In
contrast, QCRL-1, a MoAb directed against MRP1, had
no effect on Rho accumulation (data not shown). Taken
together, these results indicate that the loss of Rho ac-
cumulation in Dox-resistant endothelial cells involves
the P-gp function which has the property to mediate
cell exclusion of drugs.
We then checked cell survival after Dox treatment in
the presence of Cyclosporine A and Verapamil in both
HMECd1 and HMECd2 cells. The cells were treated
with a series of Dox concentrations in the presence of
2.5 μM Cyclosporine A or 1 μM Verapamil (that blocks
the P-gp function). The results clearly show that the
blockage of the P-gp function restored the sensitivity of
HMECd1 and HMECd2 cells to Dox (Table 1). In con-
trast, the ABCG2 inhibitors Fumitremorgin C and
Diethylstibesterol had no such effect (data not show).
Therefore, our results suggest that P-gp plays a major
role in the acquisition of Dox resistance in HMECd1
and HMECd2.
Involvement of endothelial P-gp in tumor drug resistance
To evaluate the role of endothelial P-gp in tumor protec-
tion, we also tested its influence on tumor growth in vivo.
Two groups of athymic nude mice were pretreated with
Figure 2 Endothelial cells express functional P-gp protein. Panel a and b: Verapamil blocks Rho efflux in endothelial cells. Dox- or
noninduced HMEC and HUVEC cells were incubated in the absence or presence of Rho for 1 hour at 37°C. Rho accumulation was inhibited by
the addition of Verapamil (Vrp) at 30 μM to the cell incubation mixture. The cells were analyzed in the flow cytometer. Panel c and d: Activity of
endothelial P-gp is blocked by Verapamil and MRK16. Parental HMEC, HMECd1, and HMECd2 cells were incubated with 1 μM (c) or 2 μM (d) Rho
for 1 hour at 37°C in the absence or presence of 30 μM Verapamil or 10 μg/ml MRK16 (MRK). Rho accumulation was measured by flow cytometry
and quantified as the MFI. The background fluorescence level, determined using cells not exposed to Rho, was subtracted from the data. Results
are expressed as the mean±SEM of 3 separate experiments. *p < 0.025, **p < 0.01.
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intraperitoneal (ip) Dox injection of 6 mg/kg/week over a
15-day period (groups II and IV) whereas groups I and III
were injected with physiologic serum. Groups V and VI
had no pretreatment. The Dox prescription corresponded
to the maximum well-tolerated dose of Dox and resulted
in barely 4-8% body weight loss during the experiment
and no deaths. MDA-MB-435 cells were then subcutane-
ously inoculated in the dorsal midline (groups III to VI).
The posttreatment began, corresponding to the physio-
logic serum (groups I, III, V) or Dox (II, IV, VI) injections.
The data in Figure 3a and 3b show the tumor growth evo-
lution for the different treatments. When injected after
tumor implantation, Dox effectively inhibited tumor
growth, reaching 16.4 ± 13.9 mm3 at 25 days, a 3.7-fold
decrease in tumor size compared to mice receiving
physiologic serum (60.8 ± 13.5 mm3, p < 0.025) (Figure 3b).
In contrast, when the mice had been sensitized by Dox in-
jection for 15 days before tumor implantation, the tumors
Figure 3 Induction of P-gp expression and its involvement in tumor growth in mice. Panel a. Dox pretreatment before tumor xenograft
inhibited the therapeutic efficiency of Dox therapy. Athymic mice were pretreated for 15 days with either NaCl (group III) or Dox (group IV).
Injection of MDA-MB-435 cells was performed subcutaneously in each mouse and the treatment (NaCl for group III and Dox for group IV) was
administered for 25 days. Panel b. Therapeutic efficiency was observed in Dox-treated mice who had not received Dox pretreatment. The same
experiment was performed without the 15-day pretreatment in mice receiving only NaCl (group V) or Dox (group VI). Results are expressed as the
mean ± SEM of 10 mice per group. Significant difference in tumor growth rates was found between groups V and VI (*p < 0.05), but not between
groups III and IV. Panel c: Presence of endothelial P-gp in the organs of Dox-treated mice. Livers, kidneys, and tumors from the six groups of
treated athymic mice were removed. Following digestion with collagenase, cell suspensions were filtered and washed in PBS-BSA. Endothelial
cells were isolated and characterized by flow cytometry using 10 μg/ml of control IgG or C219 antibody. The histograms represent the
percentage of endothelial cells positive for P-gp. Results are expressed as the mean ± SEM with 10 mice in each group and the experiments were
repeated at least 3 times. * : P < 0.05 in comparison to the control groups I or III without Dox treatment; ** : p < 0.05 between group IV versus
group VI. Panel d: Immunochemical staining of P-gp on the tumor sections. Red arrows indicate endothelial cells with lumen within the tumors.
The tumors were obtained and sectioned at the end of the experiments as described in above panels.
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responded poorly to Dox posttreatment and we found a
comparable tumor growth between mice receiving Dox
(55.9 ± 16.1 mm3) and physiologic serum (53.2 ± 10.3 mm3)
throughout the experiment (Figure 3a). To better under-
stand the ineffectiveness of Dox pretreatment on the
blockage of tumor growth, we sacrificed animals and
performed histological and flow cytometric studies after
cell dissociation of liver, kidneys, heart, and tumor for ten
mice in each group. This showed that the Dox treatment
given either post- or pre- and posttreatment did not sig-
nificantly modify the morphology of these organs. In par-
ticular, no sign of cardiotoxicity was observed across the
different groups.
To better quantify the P-gp positive endothelial cells
in the mice, we removed their organs and tumors. Fol-
lowing cell dissociation, the isolated endothelial cells
were characterized by flow cytometric analysis and the
percentage of endothelial cells positive for P-gp labeling
(C219) was measured (Figure 3c). Our results show that
for the liver and kidney, 10-40% of endothelial cells be-
came positive for P-gp expression following Dox pre-
and/or posttreatment (groups II, IV, and VI). Endothelial
cells within the tumor acquired the resistant phenotype
when the animals had been treated with Dox (group VI,
44.74 ± 3.55%) in comparison with buffer administration
(groups III and V, ~1%). When Dox was administered as
a pretreatment in group IV, the percentage of P-gp posi-
tive endothelial cells within the tumor reached the re-
markable level of 78.01 ± 6.39%. Immunohistological
observation of these tumor sections at the end of the ex-
periments demonstrated an induced P-gp staining on
the endothelial cells, and no evident induced P-gp stain-
ing in the surrounding tumor cells (Figure 3d). These
data suggest that endothelial cells participate in the re-
sistant phenotype of tumors by serving as an initial bar-
rier between chemotherapeutics and tumor cells.
Discussion
This study was designed to evaluate the expression of
P-gp, MRP1, and ABCG2 and their activities in endothe-
lial cells after cell exposure to Dox. We have shown for
the first time that P-gp expression was upregulated in
two stabilized Dox-resistant endothelial cells, HMECd1
and HMECd2. P-gp protein levels revealed by western
blots were found to have increased 4- and 6- fold in
both HMECd1 and HMECd2 cells. Similarly, the qPCR
experiment demonstrated 3.4 and 7.2 fold increases in
P-gp gene expression. The functional efflux test using
Rho 123 demonstrates a linear correlation between P-gp
transporter expression and efflux function. We further
show that the drug spectrum of P-gp-mediated drug re-
sistance corresponded to the P-gp functional character
and that the blockage of P-gp activity by the P-gp inhibi-
tors Verapamil and Cyclosporine A attenuated the cells’
capacity for Dox resistance. Furthermore, we demon-
strate that the resistant cell phonotype induced by Dox
treatment can be slowly reversed after withdrawal of the
drug in culture.
We studied ABCG2 because it is another well-known
ABC transporter used to efflux a wide variety of sub-
strates, in particular some anticancer drugs such as
Mitoxantrone, Doxorubicin, and Daunorubicin [29,41].
We observed a significant induction of ABCG2 expres-
sion in HMECd1 and HMECd2, though this was much
less pronounced than that of P-gp. Since both inhibitors
of ABCG2 (Fumitremorgin C and Diethylstibesterol)
failed to reverse Dox resistance in HMECd1 and HMECd2,
this also suggests that the drug efflux in HMECd1 and
HMECd2 was due to the upregulated P-gp level. MRP1
was also evaluated in this study. However, neither western
blot nor flow cytometry detected its significant expression
in noninduced cells nor was there an increase in expres-
sion in the induced cells. Accordingly, the anti-MRP1
antibody QCRL-1 MoAb had no effect on cell survival. Al-
though ABCG2 and MRP1 were shown not to be func-
tionally responsible for the drug resistance observed here,
the possibility that they may play important roles in the
drug resistance of endothelial cells in other circumstances
cannot be excluded [34,35,42].
Recent studies have emphasized the importance of
tumor vasculature and an appropriate pressure gradient
for adequate drug delivery to the tumor [43-45]. In
addition, some cancer cells that are sensitive to chemo-
therapy in cultured cell monolayers become resistant
when transplanted into animal models. This indicates
that environmental factors such as the extracellular
matrix or tumor geometry might be involved in tumor
drug resistance [46].
Our data also give rise to questions about the involve-
ment of acquired P-gp expression on endothelial cells in
tumor resistance. To induce P-gp upregulation, we firstly
treated the mice with Dox before tumor implantation.
The results of the immunostaining and cytometry ana-
lysis of the isolation of endothelial cells shown in
Figure 3 demonstrate significantly higher P-gp expres-
sion in the livers and kidneys of the treated mice,
confirming the rapid response of normal endothelial
cells to Dox challenge. These observations are in agree-
ment with the tissue distribution of P-gp [47]. We fur-
ther isolated the endothelial cells from the tumors, and
the results clearly demonstrated a higher expression of
P-gp on the tumor vessels after Dox treatment. The
highest expression of P-gp was found in those mice that
had been treated with Dox before tumor implantation,
whereas positive, but less stained, endothelial cells were
observed in the short treatment groups, compared to
the negative control mice. Immunochemical staining of
the tumor sections confirmed the result. These results
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indicate that normal vessels as well as tumor vessels
react to Dox injection. Our results are also consistent
with recent studies showing that endothelial cells iso-
lated from human tumors are less sensitive to anticancer
drugs [28,48].
To evaluate the effect of the acquired Dox resistance of
endothelial cells on tumor growth in preclinical models,
we also evaluated tumor growth in the mice where such
resistance had been induced. The results demonstrated
that Dox has an inhibitory effect on MDA-MB-435 tumor
growth transplanted into control nude mice. In the mice
that had been pretreated by Dox before tumor graft,
tumor growth continued and responded poorly to Dox
treatment. Acquired resistance to Dox in the pretreated
group is believed to greatly reduce the anti-cancer efficacy
of Dox. Importantly, as demonstrated in this model by P-
gp immune staining of the tumor sections, upregulation
of P-gp expression after Dox treatment was found essen-
tially in tumor endothelial cells, but not in tumor cells
themselves. Therefore, these results strongly suggest that
acquired resistance in tumor endothelial cells plays a role
in the overall therapeutic response to anticancer drugs.
Taken together, these findings underline the importance
of drug resistance in endothelial cells in both in vitro and
in vivo experiments. Recent reports provided evidence for
acquired drug resistance in tumor endothelial cells in can-
cer patients [36,37]. We believe that further investigation
of this aspect will be helpful in understanding the complex
mechanisms of MDR in cancer. We hope that circum-
venting endothelial cell drug resistance may improve con-
ventional chemo- and antiangiogenic therapies.
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